EP2073820A4 - Targeted polymeric prodrugs containing multifunctional linkers - Google Patents
Targeted polymeric prodrugs containing multifunctional linkersInfo
- Publication number
- EP2073820A4 EP2073820A4 EP07842578.2A EP07842578A EP2073820A4 EP 2073820 A4 EP2073820 A4 EP 2073820A4 EP 07842578 A EP07842578 A EP 07842578A EP 2073820 A4 EP2073820 A4 EP 2073820A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- containing multifunctional
- prodrugs containing
- polymeric prodrugs
- multifunctional linkers
- targeted polymeric
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G73/00—Macromolecular compounds obtained by reactions forming a linkage containing nitrogen with or without oxygen or carbon in the main chain of the macromolecule, not provided for in groups C08G12/00 - C08G71/00
- C08G73/06—Polycondensates having nitrogen-containing heterocyclic rings in the main chain of the macromolecule
- C08G73/10—Polyimides; Polyester-imides; Polyamide-imides; Polyamide acids or similar polyimide precursors
- C08G73/12—Unsaturated polyimide precursors
- C08G73/121—Preparatory processes from unsaturated precursors and polyamines
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/74—Synthetic polymeric materials
- A61K31/785—Polymers containing nitrogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
- A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/6807—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug or compound being a sugar, nucleoside, nucleotide, nucleic acid, e.g. RNA antisense
- A61K47/6809—Antibiotics, e.g. antitumor antibiotics anthracyclins, adriamycin, doxorubicin or daunomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
- C07K5/0215—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing natural amino acids, forming a peptide bond via their side chain functional group, e.g. epsilon-Lys, gamma-Glu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
- C07K5/06052—Val-amino acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06086—Dipeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0815—Tripeptides with the first amino acid being basic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G64/00—Macromolecular compounds obtained by reactions forming a carbonic ester link in the main chain of the macromolecule
- C08G64/20—General preparatory processes
- C08G64/26—General preparatory processes using halocarbonates
- C08G64/28—General preparatory processes using halocarbonates and phenols
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
- C08L71/02—Polyalkylene oxides
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US84494306P | 2006-09-15 | 2006-09-15 | |
PCT/US2007/078600 WO2008034124A2 (en) | 2006-09-15 | 2007-09-15 | Targeted polymeric prodrugs containing multifunctional linkers |
Publications (2)
Publication Number | Publication Date |
---|---|
EP2073820A2 EP2073820A2 (en) | 2009-07-01 |
EP2073820A4 true EP2073820A4 (en) | 2014-07-16 |
Family
ID=39184644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07842578.2A Withdrawn EP2073820A4 (en) | 2006-09-15 | 2007-09-15 | Targeted polymeric prodrugs containing multifunctional linkers |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP2073820A4 (en) |
JP (1) | JP2010503708A (en) |
KR (1) | KR20090057383A (en) |
CN (1) | CN101541332A (en) |
AU (1) | AU2007296056B2 (en) |
BR (1) | BRPI0716812A2 (en) |
CA (1) | CA2662981A1 (en) |
IL (1) | IL197517A0 (en) |
MX (1) | MX2009002855A (en) |
RU (1) | RU2009114154A (en) |
WO (1) | WO2008034124A2 (en) |
Families Citing this family (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP5511653B2 (en) | 2007-04-20 | 2014-06-04 | シグマ−タウ レア ディジージズ エスィアー | Stable recombinant adenosine deaminase |
EP2303288A4 (en) | 2008-05-22 | 2015-04-22 | Univ Ramot | Conjugates of a polymer, a bisphosphonate and an anti-angiogenesis agent and uses thereof in the treatment and monitoring of bone related diseases |
EP2307032A4 (en) * | 2008-05-22 | 2014-08-20 | Univ Ramot | Novel conjugates of polymers having a therapeutically active agent and an angiogenesis targeting moiety attached thereto and uses thereof in the treatment of angiogenesis related diseases |
WO2009143412A2 (en) * | 2008-05-23 | 2009-11-26 | Enzon Pharmaceuticals, Inc. | Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides |
MY151184A (en) | 2008-07-23 | 2014-04-30 | Hanmi Science Co Ltd | A polypeptide complex comprising non-peptidyl polymer having three functional ends |
US20110230420A1 (en) * | 2008-11-17 | 2011-09-22 | Enzon Pharmaceuticals, Inc. | Releasable conjugates for nucleic acids delivery systems |
WO2010057150A1 (en) * | 2008-11-17 | 2010-05-20 | Enzon Pharmaceuticals, Inc. | Releasable polymeric lipids for nucleic acids delivery systems |
US20130030359A1 (en) * | 2010-01-22 | 2013-01-31 | Ascendis Pharma A/S | Dipeptide-based prodrug linkers for aromatic amine-containing drugs |
US20130018010A1 (en) * | 2010-04-16 | 2013-01-17 | Enzon Pharmaceuticals, Inc. | Polymeric conjugates of adenine nucleoside analogs |
JP5113958B2 (en) | 2010-06-11 | 2013-01-09 | 独立行政法人科学技術振興機構 | Drug multimer fine particles and method for producing the same |
EP2646818A4 (en) * | 2010-11-30 | 2016-09-21 | Univ Illinois | Silica nanoparticle agent conjugates |
CN103045720B (en) * | 2011-10-17 | 2014-08-20 | 格诺思博生物科技(上海)有限公司 | Targeting molecule for detecting pathogenic cell and application thereof |
CN104244988A (en) | 2012-03-05 | 2014-12-24 | 雷蒙特亚特特拉维夫大学有限公司 | Polymers having therapeutically active agents conjugated thereto, processes of preparing same and uses thereof |
CN102731518B (en) * | 2012-06-26 | 2014-12-03 | 济南精合医药科技有限公司 | O-nitro aryl methoxycamptothecine anoxic activated prodrug used for antitumor drug |
CN102746316B (en) * | 2012-06-26 | 2015-04-15 | 济南精合医药科技有限公司 | An m-nitroarylmethoxy camptothecin anoxic activation prodrug for antitumor drugs |
SG11201602258WA (en) * | 2013-10-04 | 2016-04-28 | Prolynx Llc | Slow-release conjugates of sn-38 |
IL293071A (en) | 2013-10-15 | 2022-07-01 | Seagen Inc | Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics |
GB201414098D0 (en) * | 2014-08-08 | 2014-09-24 | Illumina Cambridge Ltd | Modified nucleotide linkers |
SG11201701384XA (en) | 2014-10-14 | 2017-03-30 | Polytherics Ltd | Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of peg |
KR102513926B1 (en) * | 2014-10-24 | 2023-03-23 | 폴리테릭스 리미티드 | Conjugates and conjugating reagents |
JP6570034B2 (en) * | 2014-11-26 | 2019-09-04 | 日本化薬株式会社 | Novel glutamic acid derivatives and uses thereof |
CN105641708A (en) * | 2014-12-04 | 2016-06-08 | 上海中医药大学附属普陀医院 | Polypeptide modified poly(oligo(ethylene glycol) methacrylate-co-bufalin) nano preparation, and preparation method thereof |
JP6772199B2 (en) * | 2015-08-11 | 2020-10-21 | コヒレント バイオファーマ | Multiligand-drug complex and its use |
JP6486316B2 (en) | 2015-11-03 | 2019-03-20 | 財團法人工業技術研究院Industrial Technology Research Institute | Antibody-drug conjugate (ADC) and method for forming the same |
US11793880B2 (en) | 2015-12-04 | 2023-10-24 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
AU2016363013B2 (en) | 2015-12-04 | 2022-03-10 | Seagen Inc. | Conjugates of quaternized tubulysin compounds |
WO2017165851A1 (en) | 2016-03-25 | 2017-09-28 | Seattle Genetics, Inc. | Process for the preparation of pegylated drug-linkers and intermediates thereof |
CN107375288B (en) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | The polymerization target anticancer conjugate of multi-arm |
CN106265683A (en) * | 2016-09-14 | 2017-01-04 | 江南大学 | A kind of preparation method with the pathogenic bacterium biomembrane new inhibitor wearing film targeting characteristic |
US11135307B2 (en) * | 2016-11-23 | 2021-10-05 | Mersana Therapeutics, Inc. | Peptide-containing linkers for antibody-drug conjugates |
AU2018237683A1 (en) | 2017-03-24 | 2019-10-31 | Seagen Inc. | Process for the preparation of glucuronide drug-linkers and intermediates thereof |
AU2018255458B2 (en) | 2017-04-21 | 2020-06-25 | Brightgene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
JP7231147B2 (en) * | 2017-06-29 | 2023-03-01 | 国立大学法人東海国立大学機構 | RNA introduction reagent and its use |
KR20200094185A (en) * | 2017-11-30 | 2020-08-06 | 시애틀 지네틱스, 인크. | Preparation method of drug linker compound |
BR112020013492A2 (en) | 2018-01-08 | 2020-12-08 | Regeneron Pharmaceuticals, Inc. | STEROIDS AND ANTIBODY CONJUGATES THEREOF |
JP2021510701A (en) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | Protocol and validation imaging agents to minimize the toxicity of concomitant doses |
KR102141124B1 (en) | 2018-01-30 | 2020-08-04 | (주)바이오니아 | Double-stranded Oligonucleotide Complex comprising Double― stranded miRNA and Uses thereof |
WO2019192488A1 (en) * | 2018-04-02 | 2019-10-10 | 北京键凯科技有限公司 | Cell-penetrating peptide-multiarm polyethylene glycol-drug conjugate having targeting property and application thereof |
CA3117050A1 (en) * | 2018-10-29 | 2020-05-07 | Mersana Therapeutics, Inc. | Cysteine engineered antibody-drug conjugates with peptide-containing linkers |
CA3106493C (en) * | 2018-12-17 | 2024-01-09 | Remegen, Co., Ltd. | A linker for antibody-drug conjugates and its use |
US11739166B2 (en) | 2020-07-02 | 2023-08-29 | Davol Inc. | Reactive polysaccharide-based hemostatic agent |
WO2022022354A1 (en) * | 2020-07-28 | 2022-02-03 | 重庆阿普格雷生物科技有限公司 | Polyethylene glycol conjugate drug synergist, preparation method therefor, and use thereof |
EP4190361A1 (en) * | 2020-07-28 | 2023-06-07 | Chongqing Upgra Biotechnology Co., Ltd. | Polyethylene glycol conjugate drug, and preparation method therfor and use thereof |
CN115209922A (en) * | 2021-01-28 | 2022-10-18 | 南京桦冠生物技术有限公司 | Conjugates and uses thereof |
WO2023138682A1 (en) * | 2022-01-24 | 2023-07-27 | 北京桦冠生物技术有限公司 | Conjugate and use thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
WO2003093346A1 (en) * | 2002-05-06 | 2003-11-13 | Universita' Degli Studi Di Trieste | Multifunctional polyethylene glycol derivatives: preparation and use |
WO2004014424A1 (en) * | 2002-08-13 | 2004-02-19 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004110358A2 (en) * | 2003-05-15 | 2004-12-23 | Vectramed, Inc. | Polymeric conjugates for tissue activated drug delivery |
WO2006084089A2 (en) * | 2005-02-04 | 2006-08-10 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2626654B2 (en) * | 1990-03-31 | 1997-07-02 | 科学技術振興事業団 | Targeting high molecular weight pharmaceutical compounds and intermediates thereof |
US5643575A (en) * | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US7011812B1 (en) * | 1996-05-03 | 2006-03-14 | Immunomedics, Inc. | Targeted combination immunotherapy of cancer and infectious diseases |
US6331289B1 (en) * | 1996-10-28 | 2001-12-18 | Nycomed Imaging As | Targeted diagnostic/therapeutic agents having more than one different vectors |
JP2002505574A (en) * | 1997-04-30 | 2002-02-19 | エンゾン,インコーポレイテッド | Polyalkylene oxide-modified single-chain polypeptides |
US5965119A (en) * | 1997-12-30 | 1999-10-12 | Enzon, Inc. | Trialkyl-lock-facilitated polymeric prodrugs of amino-containing bioactive agents |
US7060479B2 (en) * | 1999-12-08 | 2006-06-13 | Serono Genetics Institute, S.A. | Full-length human cDNAs encoding potentially secreted proteins |
US6153655A (en) * | 1998-04-17 | 2000-11-28 | Enzon, Inc. | Terminally-branched polymeric linkers and polymeric conjugates containing the same |
US6214330B1 (en) * | 1998-07-13 | 2001-04-10 | Enzon, Inc. | Coumarin and related aromatic-based polymeric prodrugs |
US6777387B2 (en) * | 2000-03-31 | 2004-08-17 | Enzon Pharmaceuticals, Inc. | Terminally-branched polymeric linkers containing extension moieties and polymeric conjugates containing the same |
JP2004532289A (en) * | 2001-02-20 | 2004-10-21 | エンゾン ファーマシューティカルズ,インコーポレーテッド | Terminally branched polymer linker and polymer conjugate containing the same |
US7091186B2 (en) * | 2001-09-24 | 2006-08-15 | Seattle Genetics, Inc. | p-Amidobenzylethers in drug delivery agents |
CN100475269C (en) * | 2002-03-05 | 2009-04-08 | 北京键凯科技有限公司 | Binding agent of hydrophilic polymer-glutamic acid oligopeptide and medicinal molecular, composition containing said binding agent and use thereof |
NZ542687A (en) * | 2003-04-13 | 2010-02-26 | Enzon Pharmaceuticals Inc | Polymeric oligonucleotide prodrugs |
GB0411186D0 (en) * | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
WO2006088248A1 (en) * | 2005-02-18 | 2006-08-24 | Nof Corporation | Polyoxyalkylene derivative |
-
2007
- 2007-09-15 WO PCT/US2007/078600 patent/WO2008034124A2/en active Application Filing
- 2007-09-15 EP EP07842578.2A patent/EP2073820A4/en not_active Withdrawn
- 2007-09-15 KR KR1020097005134A patent/KR20090057383A/en not_active Application Discontinuation
- 2007-09-15 BR BRPI0716812-8A patent/BRPI0716812A2/en not_active Application Discontinuation
- 2007-09-15 CA CA002662981A patent/CA2662981A1/en not_active Abandoned
- 2007-09-15 MX MX2009002855A patent/MX2009002855A/en unknown
- 2007-09-15 CN CNA2007800425870A patent/CN101541332A/en active Pending
- 2007-09-15 RU RU2009114154/15A patent/RU2009114154A/en not_active Application Discontinuation
- 2007-09-15 AU AU2007296056A patent/AU2007296056B2/en not_active Expired - Fee Related
- 2007-09-15 JP JP2009528519A patent/JP2010503708A/en active Pending
-
2009
- 2009-03-10 IL IL197517A patent/IL197517A0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6251382B1 (en) * | 1998-04-17 | 2001-06-26 | Enzon, Inc. | Biodegradable high molecular weight polymeric linkers and their conjugates |
WO2003093346A1 (en) * | 2002-05-06 | 2003-11-13 | Universita' Degli Studi Di Trieste | Multifunctional polyethylene glycol derivatives: preparation and use |
WO2004014424A1 (en) * | 2002-08-13 | 2004-02-19 | Enzon, Inc. | Releasable polymeric conjugates based on aliphatic biodegradable linkers |
WO2004110358A2 (en) * | 2003-05-15 | 2004-12-23 | Vectramed, Inc. | Polymeric conjugates for tissue activated drug delivery |
WO2006084089A2 (en) * | 2005-02-04 | 2006-08-10 | Enzon Pharmaceuticals, Inc. | Process for the preparation of polymer conjugates |
Also Published As
Publication number | Publication date |
---|---|
IL197517A0 (en) | 2009-12-24 |
AU2007296056A1 (en) | 2008-03-20 |
AU2007296056B2 (en) | 2012-09-13 |
JP2010503708A (en) | 2010-02-04 |
EP2073820A2 (en) | 2009-07-01 |
KR20090057383A (en) | 2009-06-05 |
WO2008034124A2 (en) | 2008-03-20 |
WO2008034124A3 (en) | 2008-08-07 |
RU2009114154A (en) | 2010-10-20 |
BRPI0716812A2 (en) | 2013-11-05 |
CN101541332A (en) | 2009-09-23 |
MX2009002855A (en) | 2009-03-30 |
CA2662981A1 (en) | 2008-03-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2073820A4 (en) | Targeted polymeric prodrugs containing multifunctional linkers | |
GB2438204B (en) | Gabions | |
ZA200808637B (en) | Polymers | |
EP2076257A4 (en) | Polymeric conjugates containing positively-charged moieties | |
GB0612803D0 (en) | Polymeric composition | |
EP2040758A4 (en) | Bioresponsive polymers | |
GB2456480B (en) | Airbag arrangement | |
GB2434856B (en) | Improved vehicles | |
PL2082101T3 (en) | Gutter | |
EP2118052A4 (en) | Novel prodrugs | |
HK1134928A1 (en) | Penem prodrugs | |
EP2120966A4 (en) | Polymeric short interfering rna conjugates | |
GB0604911D0 (en) | Polymers | |
EP2026825A4 (en) | Furanone-initiated polymers | |
GB0609069D0 (en) | Vehicle | |
GB0515699D0 (en) | Prodrugs | |
ZA200810520B (en) | Penem prodrugs | |
HK1149528A1 (en) | Improved vehicles | |
GB0608035D0 (en) | Vehicle | |
GB0622798D0 (en) | Phosphorus compounds | |
GB0617918D0 (en) | Polymers | |
GB0606408D0 (en) | Gabions | |
PL379893A1 (en) | Slope level | |
GB0601689D0 (en) | Aromatherapy | |
GB0605803D0 (en) | Carbon roads |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20090415 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/70 20060101AFI20090707BHEP Ipc: A61K 38/16 20060101ALI20090707BHEP |
|
DAX | Request for extension of the european patent (deleted) | ||
RAP1 | Party data changed (applicant data changed or rights of an application transferred) |
Owner name: BELROSE PHARMA INC. |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20140617 |
|
RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/70 20060101AFI20140611BHEP Ipc: A61K 38/16 20060101ALI20140611BHEP |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20150515 |